Abstract
Growth data and AH from 22 untreated patients with CD (group 1) were compared retrospectively with those of 19 patients, who had received long-acting T-esters (100 to 250 mg per month, mean total dosage 1029 mg/m2) during 2 months to 3.25 yrs (mean duraion 8.5 months, group 2). Age (group 1 15.4+/-1.2 yrs, group 2 16.2+/-1.4 yrs), BA (group 1 12.6+/-1.3 yrs, group 2 13.1+/-1.2 yrs) at first examination (group 1) or start of treatment (group 2), and AH (172.8+/-7.5 cm group 1, 176.8+/-8.0 cm group 2) were not significantly different and corresponded to target height (172.6+/-5.9 cm group 1,176.8+/-4.7 cm group 2). In group 2, there was no negative correlation between total T dose and AH, and the latter corresponded to predicted height (175.7+/-6.4 cm Bayley & Pinneau, 178.8+/-8.1 cm Roche et al., 173.9+/-6.4 cm Tanner et al.) in the same way, as in the untreated patients (175.1+/-8.1, 171.6+/-5.9,and 170.8+/-5.7 cm respectively). It is concluded that temporary treatment with long-acting T-esters (100 to 250 mg per month during 6 months, starting at a BA above 12.5 years), which has positive psychosocial and physical effects, does not have any negative somatic consequences and does not reduce AH in boys with CD. This simple and economical treatment will thus not be obsolete with recombinant hGH available in large quantities. It has the advantage of stimulating not only growth velocity, but also physical strength and development of the secondary sex characteristics.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zachmann, M., Studer, S. & Prader, A. SHORT TERM TESTOSTERONE (T) TREATMENT AT A PERIPUBERTAL BONE AGE (BA) DOES NOT REDUCE ADULT HEIGHT (AH) IN BOYS WITH CONSTITUTIONAL DELAY (CD). Pediatr Res 23, 124 (1988). https://doi.org/10.1203/00006450-198801000-00140
Issue Date:
DOI: https://doi.org/10.1203/00006450-198801000-00140